Bausch Health Companies Inc (BHC) Stock Price, Quote & News

Company Profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segm...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 514 744 6792

Website: www.bauschhealth.com

Address:

2150 St. ElzEar Boulevard West, Laval, Canada

Bullseye999 Aug. 5 at 2:58 AM

$BHC Over 35 Million purchase by the director https://finviz.com/quote.ashx?t=BHC&ty=c&ta=1&p=d

0 · Reply

thechadrandy Aug. 1 at 3:20 PM

$BHC Funny that BLCO brought BHC down.0

0 · Reply

algomezus Aug. 1 at 1:38 PM

$BHC bhc is like a hunted house horror movie. The minute you think you're finally going to escape the evil ghost shows up out of nowhere and locks you back in. I really thought we were finally going to escape. Let's see what happens. Hopefully it's just Paulson games!!

0 · Reply

ebu Aug. 1 at 2:21 AM

$BHC I can't think of any company where a stock split happened May 6th 2022. And it's shareholders are still waiting for 80% of $BLCO shares. Its unbelievable that 3 years and 3 months have past since then.

2 · Reply

jcyoung22002 Jul. 31 at 9:07 PM

$BHC did they say anything about our shares of BLCO ?😡🤬😠

1 · Reply

ZacksResearch Jul. 31 at 5:18 PM

$BHC drops 6.3% after mixed Q2 results — is there hope ahead? 🤔 📉 EPS of 90 cents missed, but total revenue beat at $2.53B, up 5% YoY 📈 Salix shines with 12% growth, led by Xifaxan demand 🧳 Bausch + Lomb's segment also shows strength, beating revenue estimates Discover if BHC can bounce back with its updated guidance 👉 https://www.zacks.com/stock/news/2644294/bausch-health-stock-falls-on-q2-earnings-miss-revenues-beat?cid=sm-stocktwits-2-2644294-body-5108&ADID=SYND_STOCKTWITS_TWEET_2_2644294_BODY_5108

0 · Reply

23ChaseColeman23 Jul. 31 at 4:59 PM

I continue to warn about $UNH and let the pros buy it $BHC is a wonderful case study

1 · Reply

thechadrandy Jul. 31 at 3:54 PM

$BHC Dog Shit

0 · Reply

ZacksResearch Jul. 31 at 3:11 PM

$BHC drops after mixed Q2 — is the rally over? Earnings missed estimates, dragging the stock down 6.3%, even as revenue came in strong with growth in Salix and Solta Medical. Full breakdown of what matters for BHC investors 👉 https://www.zacks.com/stock/news/2644294/bausch-health-stock-falls-on-q2-earnings-miss-revenues-beat?cid=sm-stocktwits-2-2644294-teaser-5043&ADID=SYND_STOCKTWITS_TWEET_2_2644294_TEASER_5043

0 · Reply

btradingwarehouse Jul. 31 at 2:52 PM

$BHC ...2BULLS... ...We are doing NOTHING !!! ...We wait ... ...Because of this price action I do not average (<$10) ...Also if you want to find out my take on this feel free to contact me (phone; FB mess.; WhatsApp) ...Because of this I switched to trading futures only !!! ... ...Stay smart

0 · Reply

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 4:05 PM EDT - 6 days ago

Bausch Health Announces Second Quarter 2025 Results

Jul 29, 2025, 2:21 PM EDT - 7 days ago

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

DRRX

Jul 29, 2025, 7:00 AM EDT - 7 days ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DRRX

Jul 29, 2025, 7:00 AM EDT - 7 days ago

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Jul 28, 2025, 9:10 AM EDT - 8 days ago

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

Jul 24, 2025, 8:02 AM EDT - 12 days ago

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

Jul 10, 2025, 5:00 PM EDT - 26 days ago

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

Jul 10, 2025, 4:15 PM EDT - 26 days ago

Bausch Health Appoints New Chief Accounting Officer

Jul 9, 2025, 8:00 AM EDT - 27 days ago

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

Jul 7, 2025, 8:00 AM EDT - 4 weeks ago

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Jul 2, 2025, 7:00 AM EDT - 4 weeks ago

Bausch Health to Announce Second Quarter 2025 Results on July 30

Jun 26, 2025, 4:30 PM EDT - 5 weeks ago

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

Jun 22, 2025, 5:00 AM EDT - 6 weeks ago

A Billionaire Trump Supporter Is Buying These Two Stocks

PPTA

Jun 18, 2025, 11:01 AM EDT - 6 weeks ago

Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares

Jun 16, 2025, 4:04 AM EDT - 7 weeks ago

Repricing Potential Driven By Deleveraging

Jun 4, 2025, 6:59 AM EDT - 2 months ago

Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

May 21, 2025, 9:45 AM EDT - 2 months ago

Facial Injectable Market Forecasts Report 2025-2030, Competitive Analysis of Key Players - Allergan, Bausch Health, Bloomage Biotechnology, and Galderma

May 21, 2025, 6:59 AM EDT - 2 months ago

Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States

May 14, 2025, 4:15 PM EDT - 2 months ago

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

May 14, 2025, 6:59 AM EDT - 2 months ago

Bausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States

May 7, 2025, 7:00 AM EDT - 3 months ago

Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens

May 6, 2025, 8:00 AM EDT - 3 months ago

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

Apr 30, 2025, 7:51 PM EDT - 3 months ago

Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 3 months ago

Bausch Health Announces First Quarter 2025 Results

Apr 29, 2025, 8:00 AM EDT - 3 months ago

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

Apr 22, 2025, 9:33 AM EDT - 3 months ago

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Apr 22, 2025, 8:54 AM EDT - 3 months ago

Bausch Health says Carl Icahn has exposure to about 34% of company's shares

Apr 22, 2025, 7:25 AM EDT - 3 months ago

Bausch Health Announces Filing of Supplement to Proxy Statement

Apr 21, 2025, 7:00 AM EDT - 3 months ago

Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Apr 17, 2025, 3:40 PM EDT - 3 months ago

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

Apr 14, 2025, 4:30 PM EDT - 4 months ago

Bausch Health Announces Adoption of Shareholder Rights Plan

Apr 10, 2025, 4:15 PM EDT - 4 months ago

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Apr 9, 2025, 8:00 AM EDT - 4 months ago

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

Apr 5, 2025, 3:00 AM EDT - 4 months ago

Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity

Apr 2, 2025, 8:00 AM EDT - 4 months ago

Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month

Mar 27, 2025, 8:44 AM EDT - 4 months ago

Bausch + Lomb recalls some of its implantable eye lenses

Mar 27, 2025, 7:30 AM EDT - 4 months ago

Bausch + Lomb Recalls EnVista Intraocular Lenses

Mar 27, 2025, 7:00 AM EDT - 4 months ago

Bausch Health to Announce First Quarter Results on April 30

Mar 27, 2025, 7:00 AM EDT - 4 months ago

Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses

Mar 26, 2025, 7:07 AM EDT - 4 months ago

Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

CHWY

Mar 25, 2025, 2:00 PM EDT - 4 months ago

Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes

Mar 21, 2025, 4:15 PM EDT - 4 months ago

Bausch Health Announces Conditional Redemption of Senior Notes

Mar 19, 2025, 11:45 AM EDT - 4 months ago

Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities

Mar 19, 2025, 11:45 AM EDT - 4 months ago

Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes

Mar 14, 2025, 9:25 AM EDT - 5 months ago

Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan

Feb 24, 2025, 10:43 AM EST - 5 months ago

Bausch Health Companies Inc. (BHC) J.P. Morgan Global Leveraged Finance Conference Transcript

Feb 21, 2025, 1:33 PM EST - 5 months ago

Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room

Feb 20, 2025, 6:01 PM EST - 5 months ago

Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)

Feb 19, 2025, 8:28 PM EST - 5 months ago

Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript

Bullseye999 Aug. 5 at 2:58 AM

$BHC Over 35 Million purchase by the director https://finviz.com/quote.ashx?t=BHC&ty=c&ta=1&p=d

0 · Reply

thechadrandy Aug. 1 at 3:20 PM

$BHC Funny that BLCO brought BHC down.0

0 · Reply

algomezus Aug. 1 at 1:38 PM

0 · Reply

ebu Aug. 1 at 2:21 AM

2 · Reply

jcyoung22002 Jul. 31 at 9:07 PM

$BHC did they say anything about our shares of BLCO ?😡🤬😠

1 · Reply

ZacksResearch Jul. 31 at 5:18 PM

0 · Reply

23ChaseColeman23 Jul. 31 at 4:59 PM

I continue to warn about $UNH and let the pros buy it $BHC is a wonderful case study

1 · Reply

thechadrandy Jul. 31 at 3:54 PM

$BHC Dog Shit

0 · Reply

ZacksResearch Jul. 31 at 3:11 PM

0 · Reply

btradingwarehouse Jul. 31 at 2:52 PM

0 · Reply

infront Jul. 31 at 2:19 PM

$BHC Turn around of a lifetime

1 · Reply

Bobberty Jul. 31 at 2:09 PM

$BHC glad I could enjoy a major ER collapse with you guys. Got the true BHC experience. Bailing out at a 10% gain here and moving on. That management team is rough.

0 · Reply

kbingo12 Jul. 31 at 2:00 PM

$BHC Icahn collecting cheap shares...he will own this and Tom is helping him. 90 days ago and at same price, Tom ponded the table for buyback...now - opps I didn't get Carl's approval so had CFO walk it back.

1 · Reply

algomezus Jul. 31 at 1:52 PM

$BHC BHC my life's mistake.

0 · Reply

Stock_Spectator Jul. 31 at 1:20 PM

$BHC $5.91

0 · Reply

Stock_Spectator Jul. 31 at 1:15 PM

$BHC and there it is….

0 · Reply

Stock_Spectator Jul. 31 at 1:07 PM

$BHC back to $5S pre market?

0 · Reply

OpenOutcrier Jul. 31 at 11:18 AM

$BHC (+3.9% pre) Bausch + Lomb raises 2025 revenue guidance to $5.15B as dry eye and contact lens growth accelerate https://ooc.bz/l/71974

0 · Reply

Bullbear1010101 Jul. 31 at 12:58 AM

$BHC probably never 200 again maybe7??

0 · Reply

kbingo12 Jul. 30 at 9:34 PM

$BHC Q1 Buyback was B.S. and when asked he defers to CFO to explain the change...what a joke...Tom has zero credibility

0 · Reply

btradingwarehouse Jul. 30 at 9:24 PM

$BHC ...2BULLS... ... ... An OUTSTANDING results with very upbeat presentation !!!

2 · Reply

GreedyBunny Jul. 30 at 9:17 PM

$BHC Granite Trust case with the IRS is over. We did not have to pay any fees. 👍

2 · Reply

Market Cap	2.14B
Revenue (ttm)	9.63B
Net Income (ttm)	-46.00M
EPS (ttm)	N/A
PE Ratio	1.52
Forward PE	1.44
Profit Margin	-0.48%
Debt to Equity Ratio	147.88

Volume	2,143,200
Avg Vol	2,066,028
Day's Range	N/A - N/A
Shares Out	370.09M
Stochastic %K	28%
Beta	0.41
Analysts	Hold
Price Target	$7.08